Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells

Dong, Matthew B., Wang, Guangchuan, Chow, Ryan D., Ye, Lupeng, Zhu, Lvyun, Dai, Xiaoyun, Park, Jonathan J., Kim, Hyunu R. +12 more·2019·Cell
DOI 10.1016/j.cell.2019.07.044

Cited by (344)

Items 101–200 of 344

  1. Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering
    Kaiyuan Tang, Liqun Zhou, Xiaolong Tian, Shao‐Yu Fang, Erica Vandenbulcke, Andrew Du, Johanna Shen, Hanbing Cao, Jerry Zhou, Krista Chen et al. · 2025 · Nature Biomedical Engineering
  2. The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer
    Tingyao Dou, Jing Li, Yaochen Zhang, Wanru Pei, Binyue Zhang, Bin Wang, Yanhong Wang, Hongyan Jia · 2024 · Frontiers in Immunology
  3. Nuclear translocation of plasma membrane protein ADCY7 potentiates T cell-mediated antitumour immunity in HCC
    Jianan Chen, Youhai Jiang, Minghui Hou, Chunliang Liu, Erdong Liu, Yali Zong, Xiang Wang, Zhengyuan Meng, Mingye Gu, Yu‐Chieh Su et al. · 2024 · Gut
  4. Ablation of FAS confers allogeneic CD3– CAR T cells with resistance to rejection by T cells and natural killer cells
    Silvia Menegatti, Sheila López‐Cobo, Aurélien Sutra Del Galy, Jaime R. Fuentealba, Lisseth E. Silva, Laëtitia Perrin, Sandrine Heurtebise-Chrétien, Valentine Pottez-Jouatte, Aurélie Darbois, Nina Burgdorf et al. · 2024 · Nature Biomedical Engineering
  5. Cationic polymer synergizing with a disulfide-containing enhancer achieved efficient nucleic acid and protein delivery
    Yuanji Feng, Zhaopei Guo, Jie Chen, Sijia Zhang, Jiayan Wu, Huayu Tian, Xuesi Chen · 2022 · Biomaterials Science
  6. The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells
    Xiaofeng Liao, Wenxue Li, Hongyue Zhou, Barani Kumar Rajendran, Ao Li, Jingjing Ren, Yi Luan, David Calderwood, Benjamin E. Turk, Wenwen Tang et al. · 2024 · Nature Communications
  7. Metabolic immunoengineering approaches to enhance CD8+ T cell-based cancer immunotherapy
    Bing Feng, Rongrong Li, Weilin Li, Li Tang · 2024 · Cell Systems
  8. High-content CRISPR screening in tumor immunology
    Erin A. Holcomb, Ashley N. Pearson, Kassidy Mikala Jungles, Akshay Tate, Jadyn G. James, Long Jiang, Amanda K. Huber, Michael D. Green · 2022 · Frontiers in Immunology
  9. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer
    Samantha M. Fix, Amir Anthony Jazaeri, Patrick Hwu · 2021 · Cancer Discovery
  10. Designing custom CRISPR libraries for hypothesis-driven drug target discovery
    Vaishnavi Srinivasan Iyer, Long Jiang, Yunbing Shen, Sanjaykumar V. Boddul, Sudeepta Kumar Panda, Zsolt Kasza, Bernhard Schmierer, Fredrik Wermeling · 2020 · Computational and Structural Biotechnology Journal
  11. Interrogating immune cells and cancer with CRISPR-Cas9
    Frank A. Buquicchio, Ansuman T. Satpathy · 2021 · Trends in Immunology
  12. DHX37 and 46,XY DSD: A New Ribosomopathy?
    Ken McElreavey, Éric Pailhoux, Anu Bashamboo · 2022 · Sexual Development
  13. Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness
    Chun‐Pu Lin, Pierre L. Levy, Astrid Alflen, Georgi Apriamashvili, Maarten Alexander Ligtenberg, David W. Vredevoogd, Onno B. Bleijerveld, Ferhat Alkan, Yuval Malka, Liesbeth Hoekman et al. · 2024 · Cancer Cell
  14. Transforming cancer treatment: integrating patient-derived organoids and CRISPR screening for precision medicine
    Ziyi Zhu, Jiayang Shen, Paul C. Ho, Ya‐Han Hu, Zhaowu Ma, Lingzhi Wang · 2025 · Frontiers in Pharmacology
  15. Cancer systems immunology
    Nathan Edward Reticker-Flynn, Edgar G. Engleman · 2020 · eLife
  16. Advancements in CRISPR screens for the development of cancer immunotherapy strategies
    Yan-Ruide Li, Zibai Lyu, Yanxin Tian, Ying Fang, Yichen Zhu, Yuning Chen, Lili Yang · 2023 · Molecular Therapy — Oncolytics
  17. Genome-wide CRISPR/Cas9 screening for drug resistance in tumors
    Zhongyan Zhang, Hailiang Wang, Qian Yan, Jinwei Cui, Yubin Chen, Shiye Ruan, Jiayu Yang, Zelong Wu, Mingqian Han, Shanzhou� Huang et al. · 2023 · Frontiers in Pharmacology
  18. Bioinformatics approaches to analyzing CRISPR screen data: from dropout screens to single‐cell CRISPR screens
    Yueshan Zhao, Min Zhang, Da Yang · 2022 · Quantitative Biology
  19. Regulation and function of poised mRNAs in lymphocytes
    Martin Turner · 2023 · BioEssays
  20. Compact CRISPR genetic screens enabled by improved guide RNA library cloning
    Seok‐Jin Heo, Lauren D. Enriquez, Scot Federman, Amy Y. Chang, Rachel Mace, Kaivalya Shevade, Phuong Nguyen, Adam J. Litterman, Shawn Shafer, Laralynne Przybyla et al. · 2024 · Genome biology
  21. CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy
    Mingming Qin, Chunhao Deng, Liewei Wen, Guoqun Luo, Ya Meng · 2024 · Journal of Translational Medicine
  22. CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma
    Fahreddin Palaz, Mehmet Özsöz, Ali Zarrinpar, İlyas Şahin · 2024 · Journal of Hepatocellular Carcinoma
  23. Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology
    A Vipin Menon, Bicna Song, Lumen Chao, Diksha Sriram, Pamela A. Chansky, Ishnoor Bakshi, Jane Ulianova, Wei Li · 2025 · Frontiers in Genome Editing
  24. Multiplexed engineering and precision gene editing in cellular immunotherapy
    Alexander Biederstädt, Gohar Shahwar Manzar, May Daher · 2022 · Frontiers in Immunology
  25. Functional Screening Techniques to Identify Long Non-Coding RNAs as Therapeutic Targets in Cancer
    Kathleen M. Lucere, Megan M. R. O’Malley, Sarah D. Diermeier · 2020 · Cancers
  26. Optimization of CRISPR–Cas system for clinical cancer therapy
    Xiang Ling Meng, Tiangang Wu, Qiuyue Lou, Kaiyuan Niu, Lei Jiang, Qing‐zhong Xiao, Tao Xu, Lei Zhang · 2022 · Bioengineering & Translational Medicine
  27. Cuproptosis-Related Ferroptosis genes for Predicting Prognosis in kidney renal clear cell carcinoma
    Gang Luo, Lini Wang, Ziyu Zheng, Baobao Gao, Chong Lei · 2023 · European journal of medical research
  28. Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway
    Jun Yang · 2024 · British Journal of Cancer
  29. Multiparametric Assays for Accelerating Early Drug Discovery
    Alexander Herholt, Sabrina Galinski, Philipp Emanuel Geyer, Moritz J. Rossner, Michael C. Wehr · 2020 · Trends in Pharmacological Sciences
  30. p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy
    Chunwan Lu, John David Klement, Alyssa D. Smith, Dafeng Yang, Jennifer L. Waller, Darren D. Browning, David H. Munn, Kebin Liu · 2020 · Journal for ImmunoTherapy of Cancer
  31. CRISPR activation screen in mice identifies novel membrane proteins enhancing pulmonary metastatic colonisation
    Louise van der Weyden, Victoria J. Harle, Gemma Turner, Victoria Offord, Vivek Iyer, Alastair Droop, Agnieszka Świątkowska, Roy Rabbie, Andrew D. Campbell, Owen James Sansom et al. · 2021 · Communications Biology
  32. Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review
    Peiwen Ma, Yale Jiang, Guo Zhao, Wenbo Wang, Shujun Xing, Qiyu Tang, Huilei Miao, Hong Fang, Sun Chao, Fang Yuan et al. · 2024 · European Journal of Cancer
  33. Application of CRISPR screen in mechanistic studies of tumor development, tumor drug resistance, and tumor immunotherapy
    Min Li, Jin Sun, Guohai Shi · 2023 · Frontiers in Cell and Developmental Biology
  34. Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer
    Kennady K. Bullock, Ann Richmond · 2024 · Cancers
  35. CRISPR/Cas9 screening: unraveling cancer immunotherapy’s ‘Rosetta Stone’
    Baoxiang Chen, Yanrong Deng, Xianghai Ren, Jianhong Zhao, Congqing Jiang · 2024 · Trends in Molecular Medicine
  36. Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity
    Jonathan Joon-Young Park, Adan Codina, Lupeng Ye, Stanley Z. Lam, Jianjian Guo, Paul R. Clark, Xiaoyu Zhou, Lei Peng, Sidi Chen · 2022 · Journal of Hematology & Oncology
  37. A STUB1–CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity
    Martin W. LaFleur, Lauren E. Milling, P. T. Prathima, Vivian Li, Ashlyn M. Lemmen, Ivy S. L. Streeter, Paul K S Heisig, Nicole M. Derosia, Elizabeth N. Riffo, Haonan Xu et al. · 2025 · Nature Immunology
  38. CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy
    Valentine De Castro, Jeanne Galaine, Romain Loyon, Yann Godet · 2024 · Cancer Gene Therapy
  39. Human effector CD8+ T cells with an activated and exhausted-like phenotype control tumour growth in vivo in a humanized tumour model
    Juliane Mietz, Meike Kaulfuß, Lukas Egli, Lennart Opitz, Christian Münz, Obinna Chijioke · 2024 · EBioMedicine
  40. Integrative Expression and Prognosis Analysis of DHX37 in Human Cancers by Data Mining
    Kang Huang, Tudi Pang, Chang-Jun Tong, Houqing Chen, Yupeng Nie, Jiayi Wu, Yandong Zhang, Ganghong Chen, Wei Zhou, Dazhi Yang · 2021 · BioMed Research International
  41. Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8 + T cell exhaustion-suppressed antitumor immunity
    Guolong Liu, Xiaoling Tian, Qiudao Wang, Saijuan Xu, Yanhong Jiang, Ying Gao, Yuxuan Wu · 2025 · Science Advances
  42. Engineering stimuli-responsive nanocarriers for CRISPR/Cas9 genome editing: next-generation cancer therapeutics
    Sivaraj Mehnath · 2025 · Journal of Pharmacy and Pharmacology
  43. CRISPR Screens to Identify Regulators of Tumor Immunity
    Martin W. LaFleur, Arlene H. Sharpe · 2021 · Annual Review of Cancer Biology
  44. DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration
    Yanni Xu, Qiongchao Jiang, Hejun Liu, Xiaoyun Xiao, Dinghong Yang, Phei Er Saw, Baoming Luo · 2020 · Journal of Immunology Research
  45. Recent Advances in Cancer Drug Discovery Through the Use of Phenotypic Reporter Systems, Connectivity Mapping, and Pooled CRISPR Screening
    Natasha Salame, Katharine Fooks, Nehmé El-Hachem, Jean‐Pierre Bikorimana, François Mercier, Moutih Rafei · 2022 · Frontiers in Pharmacology
  46. Framework for in vivo T cell screens
    Lauren E. Milling, Samuel C. Markson, Qin Tjokrosurjo, Nicole M. Derosia, Ivy S. L. Streeter, Grant H. Hickok, Ashlyn M. Lemmen, Thao H. Nguyen, Priyamvada Prathima, William Fithian et al. · 2024 · The Journal of Experimental Medicine
  47. A microRNA-regulated transcriptional state defines intratumoral CD8+ T cells that respond to immunotherapy
    William Weihao Tang, Ben Battistone, Kaylyn M. Bauer, Allison M. Weis, Cindy Barba, Muhammad Zaki Hidayatullah Fadlullah, Arevik Ghazaryan, Van B. Tran, Soh-Hyun Lee, Z Busra Agir et al. · 2025 · Cell Reports
  48. Common computational tools for analyzing CRISPR screens
    Medina Colic, Traver Hart · 2021 · Emerging Topics in Life Sciences
  49. Genome-wide CRISPR/Cas9 screen identifies host factors important for porcine reproductive and respiratory syndrome virus replication
    Jinhe Jiang, Yumei Sun, Yunlong Wang, Ahmed Sabek, Aishao Shangguan, Kai Wang, Shuhong Zhao, Guoliang Li, Ao Zhou, Shujun Zhang · 2022 · Virus Research
  50. Applications of CRISPR technology in cellular immunotherapy
    Xiaoyu Zhou, Paul A. Renauer, Liqun Zhou, Shao‐Yu Fang, Sidi Chen · 2023 · Immunological Reviews
  51. Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors
    Chirine Rafia, Christelle Harly, Emmanuel Scotet · 2020 · Immunological Reviews
  52. PILRα on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity
    Lin Xia, Junyi Liu, Chao Yu, Hongwei Lin, Ya-hong Hu, Guo-Sheng Hu, Yaohui He, Yun-yao Chen, Wenxin Luo, Ningshao Xia et al. · 2025 · Nature Cancer
  53. In vivo delivery systems for CRISPR genome editing: Viral and non-viral carriers
    Yeeun Lee, Bookun Kim, Donghyun Lee, Seo Young Cheon, Seong Gi Lim, Younggwang Kim, Heebeom Koo · 2025 · Applied Physics Reviews
  54. CRISPR-Based Editing Techniques for Genetic Manipulation of Primary T Cells
    Mateusz Kotowski, Sumana Sharma · 2020 · Methods and Protocols
  55. A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem
    Benjamin J. McLean, Aji Istadi, Teleri Clack, Mezzalina Vankan, Daniel Schramek, G. Gregory Neely, Marina Pajic · 2022 · Advanced Genetics
  56. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy
    Margaret A. Potts, Jackson A. McDonald, Kate D Sutherland, Marco J. Herold · 2020 · European Journal of Immunology
  57. Engineering NK and T cells with metabolite-sensing receptors to target solid tumors
    Young‐Min Kim, Min K. Tsai, Chang Sun, Olivia Laveroni, Reece Villarin Akana, Kristen R. Frombach, Livnat Jerby‐Arnon · 2026 · Nature Immunology
  58. In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis
    Juan Martín Arriaga, Kacey Ronaldson-Bouchard, Florencia Picech, Francisca Nunes de Almeida, Stephanie N. Afari, Houssein Chhouri, Gordana Vunjak‐Novakovic, Cory T. Abate-Shen · 2024 · Oncogene
  59. Efficient prioritization of CRISPR screen hits by accounting for targeting efficiency of guide RNA
    Byung-Sun Park, Heeju Jeon, Sung‐Gil Chi, Tackhoon Kim · 2023 · BMC Biology
  60. Identification of druggable regulators of cell secretion via a kinome-wide screen and high-throughput immunomagnetic cell sorting
    Mahmoud Labib, Zongjie Wang, Yunhye Kim, Sichun Lin, Abdalla Abdrabou, Hanie Yousefi, Pei-Ying Lo, Stéphane Angers, Edward Hartley Sargent, Shana O. Kelley · 2023 · Nature Biomedical Engineering
  61. Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages
    Zemeng Ma, Xiaoyao Hao, Shuang Qu, Quanli Zhang, Jiajing Luo, Hongyan Li, Jinyu Liu, Wenwen Dai, Jun Li, Shouyong Gu et al. · 2025 · Journal for ImmunoTherapy of Cancer
  62. Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy
    Meijun Si, Jingpeng Fu, Mengting Fang, Yunfei Lu, Junxuan Huang, Haojie Li, Peiyi Wang, Maofu Liao, Jian Zhu, Peiyao Li et al. · 2025 · Nature Communications
  63. Evaluation and prediction of guide RNA activities in genome-editing tools
    Hui Kwon Kim, Seokjoong Kim · 2025 · Nature Reviews Bioengineering
  64. Applying CRISPR-Cas9 screens to dissect hematological malignancies
    Deepak Narayanan Iyer, Aaron David Schimmer, Hong Chang · 2022 · Blood Advances
  65. Genome-wide CRISPR screens for the identification of therapeutic targets for cancer treatment
    Vivian Weiwen Xue, Sze Chuen Cesar Wong, William Chi Shing Cho · 2020 · Expert Opinion on Therapeutic Targets
  66. Significance of CD8+ T cell infiltration-related biomarkers and the corresponding prediction model for the prognosis of kidney renal clear cell carcinoma
    Yuan Tian, Yumei Wei, Hongmei Liu, Heli Shang, Yuedong Xu, Tong Wu, Wei Liu, Alan Huang, Qi Dang, Yuping Sun · 2021 · Aging
  67. High-throughput CRISPR technology: a novel horizon for solid organ transplantation
    Xiaohan Li, Zhang Chen, Weicong Ye, Jizhang Yu, Xi Zhang, Yuan Li, Yuqing Niu, Shuan Ran, Song Wang, Zilong Luo et al. · 2024 · Frontiers in Immunology
  68. FBXO38 is dispensable for PD-1 regulation
    Nikol Dibus, Eva Šályová, Karolína Kolářová, Alikhan Abdirov, Michele Pagano, Ondřej Štěpánek, Lukáš C̆ermák · 2024 · EMBO Reports
  69. Dietary nucleic acids promote oral tolerance through innate sensing pathways in mice
    Tao Yang, Li Tian, Yingying Xing, Mengtao Cao, Mingxiang Zhang, Qibin Leng, Ju Qiu, Xinyang Song, Jianfeng Chen, Guohong Hu et al. · 2024 · Nature Communications
  70. RNA-binding proteins and ribonucleoproteins as determinants of immunity
    Martin Turner, Georg Petkau · 2026 · Nature reviews. Immunology
  71. Recent Advances and Therapeutic Strategies Using CRISPR Genome Editing Technique for the Treatment of Cancer
    Shreyasi Maity, Rishyani Mukherjee, Satarupa Banerjee · 2022 · Molecular Biotechnology
  72. A novel DEAH-box helicase 37 mutation associated with differences of sex development
    Yun Wan, Richeng Yu, Jianhua Luo, Ping Cheong Huang, Xingju Zheng, Liqun Sun, Kui Ru Hu · 2023 · Frontiers in Endocrinology
  73. Construction and validation of a signature for T cell-positive regulators related to tumor microenvironment and heterogeneity of gastric cancer
    Yangyang Guo, Yingjue Zhang, Kenan Cen, Ying Dai, Yifeng Mai, Kai Mun Hong · 2023 · Frontiers in Immunology
  74. How CRISPR/Cas9 Gene Editing Is Revolutionizing T Cell Research
    Kristoffer Haurum Johansen · 2021 · DNA and Cell Biology
  75. In Vivo Cancer-Based Functional Genomics
    Chennan Li, Andrea L. Kasinski · 2020 · Trends in cancer
  76. Comprehensive strategies for constructing efficient CRISPR/Cas based cancer therapy: Target gene selection, sgRNA optimization, delivery methods and evaluation
    Sathishbabu Paranthaman, Chinnappa A. Uthaiah, Shadab Md, Huda Mohammed Alkreathy · 2025 · Advances in Colloid and Interface Science
  77. The potential application of stroma modulation in targeting tumor cells: Focus on pancreatic cancer and breast cancer models
    Giuseppina Roscigno, S. Jacobs, Belén Toledo, Roberto Borea, Gianluca Russo, Francesco Pepe, María José Serrano, Viola Calabrò, Giancarlo Troncone, Roberto Giovannoni et al. · 2025 · Seminars in Cancer Biology
  78. The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens
    David W. Vredevoogd, Georgi Apriamashvili, Daniel S. Peeper · 2021 · Immuno-Oncology Technology
  79. Machine Learning Screens Potential Drugs Targeting a Prognostic Gene Signature Associated With Proliferation in Hepatocellular Carcinoma
    Jun Liu, Jianjun Lu, Wenli Li, Wenjie Mao, Yamin Lu · 2022 · Frontiers in Genetics
  80. CRISPR-based genetic screens advance cancer immunology
    Yuanfang Cao, Xueting Li, Yumu Pan, Huahe Wang, Siyu Yang, Lingjuan Hong, Lupeng Ye · 2024 · Science China Life Sciences
  81. Food nutrition and toxicology targeting on specific organs in the era ofsingle-cell sequencing
    Xiaofei Wang, Xiao‐Wen Cheng, Huiling Liu, Xiaohuan Mu, Hao Zheng · 2023 · Food Science and Human Wellness
  82. Developing an Arrayed CRISPR-Cas9 Co-Culture Screen for Immuno-Oncology Target ID
    Sarah Gee, Nadine Nelson, Aurélie Bornot, Nikki Carter, Maria Emanuela Cuomo, Simon J. Dovedi, Paul D. Smith, Davide Gianni, David J. Baker · 2020 · SLAS DISCOVERY
  83. CRISPR in medicine: applications and challenges
    Jin‐Yu Sun, Haibo Hu, Yanxiang Cheng, Xiaojie Lu · 2020 · Briefings in Functional Genomics
  84. High-throughput screening for optimizing adoptive T cell therapies
    Yuchen Zhang, Qinglong Xu, Zhifei Gao, Honghao Zhang, Xiaoling Xie, Meifang Li · 2024 · Experimental Hematology and Oncology
  85. Preclinical Models of Solid Cancers for Testing Cancer Immunotherapies
    Francisco Expósito, Kelli A. Connolly, Tang Tang, Michael Chiorazzi, Brian G. Hunt, Jordan J. Cardenas, Don X. Nguyen, Nikhil S. Joshi, Katerina A. Politi · 2025 · Annual Review of Cancer Biology
  86. Tumor immune evasion: insights from CRISPR screens and future directions
    Tirta Mario Djajawi, Johannes Wichmann, Stephin J. Vervoort, Conor J. Kearney · 2023 · FEBS Journal
  87. From gene editing to tumor eradication: The CRISPR revolution in cancer therapy
    Ashiq Ali, Urooj Azmat, Aisha Khatoon, Kaynaat Akbar, Bilal Murtaza, Ziyi Ji, Urooj Irshad, Zhongjing Su · 2025 · Progress in Biophysics and Molecular Biology
  88. Metabolic traits ruling the specificity of the immune response in different cancer types
    Nina C. Flerin, Federica Cappellesso, Samantha Pretto, Massimiliano Mazzone · 2020 · Current Opinion in Biotechnology
  89. Ferroptosis and its relationship with cancer
    Chuanchao Su, Yiwen Xue, Siyu Fan, Xin Sun, Qian Si, Zhen Gu, Jingfei Wang, Runzhi Deng · 2025 · Frontiers in Cell and Developmental Biology
  90. CRISPR screening approaches in breast cancer research
    Mark E. Samuels, Simoni Besta, Andrea Lauer Betrán, Reza Shirazi Nia, Xiaohong Xie, Xidong Gu, Qijin Shu, Georgios Giamas · 2025 · Cancer and Metastasis Reviews
  91. Efferocytosis‐Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer
    Wenhan Li, Feiquan Ying, Xinkai Pang, Qiulei Wu, Guoqing Li, Lin Huang, Jiayu Xin, Xiaoli Liu, Pan Liu, Xiaohan Xu et al. · 2025 · Advanced Science
  92. CRISPR Technology: Transforming the Future of Medicine and Diagnostics
    Kavita A. Iyer, Rumiana Tenchov, Leilani M. Lotti Diaz, Preeti Jain, Trupti Thite, Yi Deng, Qiongqiong Angela Zhou · 2025 · Biochemistry
  93. DHX37 Is a Promising Prognostic Biomarker and a Therapeutic Target for Immunotherapy and Chemotherapy in HCC
    Nanbin Liu, Hailong Zhang, Chunli Zhang, Zeyu Li, Limin Huang, Jin Sun, Jun'an Qi, Xi Deng, Na Huang, Yanhua Mu et al. · 2023 · Cancers
  94. Expanding the CAR toolbox with high throughput screening strategies for CAR domain exploration: a comprehensive review
    G. Roex, Khloe S. Gordon, E. Lion, Michael E. Birnbaum, S. Anguille · 2025 · Journal for ImmunoTherapy of Cancer
  95. Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials
    Christopher R. Cabanski, Enjun Yang, Mark D. Stewart, Jeff D. Allen, John E Connolly, Ute Dugan, Philip D. Greenberg, Crystal Lee Mackall, Carl H. June, Alexander Marson et al. · 2025 · Journal for ImmunoTherapy of Cancer
  96. CRISPR/Cas9 in Male Factor Infertility
    Davide Cina, Drew Phillips, Ryan Kendrick Flannigan · 2020 · Current Tissue Microenvironment Reports
  97. Unveiling immune checkpoint regulation: exploring the power of in vivo CRISPR screenings in cancer immunotherapy
    Yuxiang Wang, Athar Khalil, Amina Kamar, Mengyan Du, Trang Dinh, Christopher D. McFarland, Zhenghe Wang · 2023 · Frontiers in Genetics
  98. Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci
    Christos Miliotis, Yuling Ma, Xanthi-Lida Katopodi, Dimitra Karagkouni, Eleni Kanata, Kaia Mattioli, Nikolaos Kalavros, Yered H. Pita-Juárez, Felipe Batalini, Varune Rohan Ramnarine et al. · 2024 · Nature Communications
  99. Tumor microenvironment derived signature predicting relapse-free survival in I-III cancer and preliminary experiment verification
    Zhiyuan Zhang, Qi Wu, Dexiang Zhu, Guodong He, Qingyang Feng, Jianmin Xu · 2020 · International Immunopharmacology
  100. In vitro and in vivo CRISPR-Cas9 screens reveal drivers of aging in neural stem cells of the brain
    Tyson Joel Ruetz, Chloe M. Kashiwagi, Bhek Morton, Robin W. Yeo, Dena S. Leeman, David W. Morgens, C. Kimberly Tsui, Amy Li, Michael Cory Bassik, Anne Brunet · 2021 · bioRxiv (Cold Spring Harbor Laboratory)